IN8bio Inc (INAB) News

Form EFFECT - Notice of Effectiveness

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at...

IN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting

Plenary Oral Presentation at SNO will provide latest clinical trial results from the previously enrolled...

IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting

NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical...

Form S-3 - Registration statement under Securities Act of 1933

Form D - Notice of Exempt Offering of Securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

IN8bio Announces Pricing of $12.4 Million Private Placement

Cash position now expected to fund current operating plan into 2026 Financing provides cash runway to advance...

Form 8-K - Current report